#Japan #Tokyo #ADC technology #Fujifilm #Taiho Pharmaceutical

Strategic Partnership for Advanced ADC Technology

Taiho Pharmaceutical Co., Ltd., headquartered in Chiyoda, Tokyo, has officially announced a strategic partnership with Fujifilm Corporation, based in Minato, Tokyo, aimed at developing cutting-edge manufacturing technologies for next-generation antibody-drug conjugates (ADCs). This collaboration intends to optimize manufacturing processes and establish a reliable system for producing high-quality ADCs, thereby enhancing global competitiveness in this burgeoning field.

As a part of this alliance, the two companies will utilize the AraLinQ™ technology created by Araris Biotech AG, a subsidiary of Taiho. This technology focuses on the effective production of ADC candidates developed by Taiho, which emphasizes the merging of Taiho's expertise in ADC drug discovery with Fujifilm’s advanced process development and manufacturing capabilities in contract development and manufacturing organization (CDMO).

The Rise of ADCs in Biopharmaceuticals

The last few years have seen significant interest in ADCs, which combine antibodies and chemotherapy agents. These biopharmaceuticals are anticipated to deliver high therapeutic efficacy while minimizing side effects, making them a promising addition to cancer treatment regimens. However, the complexity of manufacturing ADCs—specifically the precise conjugation of antibodies and drugs—presents significant challenges. Consequently, establishing a robust and efficient manufacturing system has become crucial.

Taiho Pharmaceutical is actively dedicated to enhancing the manufacturing and supply system for next-generation ADCs using the AraLinQ™ platform. This innovative technology facilitates the selective and uniform binding of drugs to antibodies, establishing it as a groundbreaking ADC production method.

Fujifilm has a well-established global footprint in the bio CDMO sector, boasting extensive experience in the development and manufacturing of antibody pharmaceuticals. Additionally, its group company, Fujifilm Toyama Chemical, is planning to launch integrated ADC manufacturing services domestically by 2027, making it the first of its kind in Japan. The aim is to create a seamless process from antibody production to conjugation and formulation, thereby meeting the growing demand for ADCs in the Japanese market.

Future Directions and Enhancements

Moving forward, Taiho Pharmaceutical and Fujifilm will leverage their strengths within this partnership to focus on optimizing production processes for stable ADC manufacturing. As the development of ADC candidates progresses, the collaboration aims to bolster technical cooperation while reinforcing the manufacturing technology framework to ensure a continuous supply of these innovative therapies.

Understanding Antibody-Drug Conjugates (ADCs)

ADCs represent a unique class of medicines that combine specific targeting antibodies with cytotoxic drugs. By delivering therapeutic agents selectively to target cells through antibodies, ADCs aim to achieve enhanced therapeutic effects alongside reduced side effects, marking their role as a priority focus in global biopharmaceutical research.

About Taiho Pharmaceutical Co., Ltd.

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is committed to enhancing public health with its corporate philosophy: "We contribute to the creation of a society rich in smiles and good health." Specializing in oncology and immunological diseases, Taiho is recognized as a leading firm in the oncology sector within Japan and is actively promoting globalization efforts. The company also emphasizes creating products that can improve the quality of life beyond oncology. For more details, visit Taiho Pharmaceutical's website.

About Fujifilm Corporation

Fujifilm Corporation, a key player in the Fujifilm Group, harnesses its unique core technologies and extensive expertise to deliver innovative products and services through four business segments: healthcare, electronics, business innovation, and imaging. With over 70,000 employees worldwide, Fujifilm aims to solve social challenges and create positive impacts through its products, services, and business activities encapsulated in its group purpose: "Increasing the number of smiles on Earth." For more information, please refer to Fujifilm's official website. Additionally, details about their sustainability and CSR initiatives can be found under the 'Sustainable Value Plan 2030' section on their site.